Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/28/2022* -- Results Q3 2022 -- -3.37 --
10/28/2022* -- Earnings Call Q3 2022 -- -- --
07/28/2022 08:30 EST Earnings Call Q2 2022 -- -- --
07/28/2022 -- Results Q2 2022 -3.84 -4.59 16.36%
05/05/2022 -- Results Q1 2022 -4.38 -5.02 12.72%
05/05/2022 08:30 EST Earnings Call Q1 2022 -- -- --
03/03/2022 -- Results Q4 2021 -4.76 -4.87 2.32%
03/03/2022 08:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/28/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/28/2022
Beat/Miss Upgrade
Return Since -5.89%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines. argenx developed and is commercializing the neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others.
URL https://www.argenx.com
Investor Relations URL https://www.argenx.com/investors
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Oct. 28, 2022 (est.)
Last Earnings Release Jul. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
52.15%
67.09%
83.21%
19.08%
0.23%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-22.58%
--
-45.38%
71.98%
-42.88%
2.82%
58.06%
-69.99%
-70.69%
--
--
--
-18.71%
-40.41%
21.74%
-4.00%
36.01%
92.92%
62.96%
30.19%
239.4%
57.53%
-77.19%
-31.08%
-66.47%
--
--
-9.75%
-69.24%
8.88%
25.15%
-74.54%
-76.99%
As of September 27, 2022.

Profile

Edit
argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines. argenx developed and is commercializing the neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others.
URL https://www.argenx.com
Investor Relations URL https://www.argenx.com/investors
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Oct. 28, 2022 (est.)
Last Earnings Release Jul. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
BBH 17.21M USD 4.17%
PWJDX 155.86M USD 3.88%
APDIX 223.47M USD 3.73%
FBIOX 166.42M USD 3.30%
GDOC 2.496M USD 2.69%
THISX 338.72M USD 2.18%
FDG 2.517M USD 2.10%
FSPHX 176.64M USD 2.07%
BMEZ 39.52M USD 1.86%
TRUZX 406.35M USD 1.76%
IBB 113.70M USD 1.56%
HQL 4.375M USD 0.90%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ARGX Tweets